Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has provided an update.
Recce Pharmaceuticals has signed a new Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to evaluate its RECCE 327 Gel in a validated burn wound infection model that mimics battlefield injuries. The study will assess the gel’s ability to reduce bacterial burden from Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa, two major pathogens in burn patients, reinforcing Recce’s growing collaboration with U.S. government agencies and highlighting the product’s potential use as a frontline hydrogel dressing for combat, clinical and post-operative wound care amid rising antimicrobial resistance.
The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.53 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Limited is an Australia-based biotechnology company developing a new class of synthetic, broad-spectrum anti-infectives, with lead product RECCE 327 and its topical gel formulation targeting difficult-to-treat bacterial infections, including multidrug-resistant superbugs, across military and civilian healthcare settings.
Average Trading Volume: 137,813
Technical Sentiment Signal: Buy
Current Market Cap: A$161.9M
For a thorough assessment of RCE stock, go to TipRanks’ Stock Analysis page.